In Support of SB 111 and 112-Expanded access to expungement rstreet.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rstreet.org Daily Mail and Mail on Sunday newspapers.
India is stepping back from importing ferrous scrap and aiming to become a more self-sufficient steelmaker. But what issues led to this change of tactics and how will it affect global scrap trade flows? Fastmarkets investigates.
The global scrap market is under pressure from a variety of challenging conditions - from a Covid-19-related shortage of shipping containers, to port delays and rising port and freight charges.
This combination of factors has resulted in one key scrap market looking to move away from imported material and India s steel industry is now aiming to meet its needs using domestic raw materials under prime minister Narendra Modi s ‘Atmanirbhar Bharat’ policy - which translates as ‘self-reliant India’.
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million
RP Management, LLCApril 8, 2021 GMT
Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments
NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. OXLUMO, which has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of primary hyperoxaluria (PH) type 1, is marketed by Alnylam Pharmaceuticals, Inc. (“Alnylam”).
In SUPPORT of HB 271, AN ACT concerning Public Safety- Law Enforcement Diversion Programs rstreet.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rstreet.org Daily Mail and Mail on Sunday newspapers.